Search results
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Motley Fool via Yahoo Finance· 3 days agoBy almost any measure, AbbVie (NYSE: ABBV) shares should have risen Friday. The pharmaceutical giant...
Drugmaker AbbVie expects Humira volume erosion to worsen
Reuters via Yahoo News· 3 days ago(Reuters) -AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen...
AbbVie Q1 Preview: Skyrizi and Rinvoq’s launches could help Q1 (NYSE:ABBV)
Seeking Alpha· 4 days agoAbbVie (ABBV) is set to report Q1 earnings results on April 26th. Analysts expect a profit of $2.26...
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
Reuters via AOL· 4 days agoRinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a...
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 3 days agoImage source: The Motley Fool. AbbVie (NYSE: ABBV) Q1 2024 Earnings Call Apr 26, 2024, 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call...
AbbVie's newer drugs are offsetting losses of the world's once best-selling medication
Quartz· 3 days agoSales of the pharma giant's newer drugs are offsetting its Humira losses.
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
Zacks via Yahoo Finance· 3 days agoAbbVie Inc. ABBV reported adjusted earnings of $2.31 per share for first-quarter 2024, beating the...
AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That
Investor's Business Daily· 3 days agoAbbVie is "firing on all cylinders," an analyst said Friday after the pharma giant beat Wall...
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study By...
Investing.com· 4 days agoAbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
AbbVie raises annual profit forecast on strong Skyrizi sales
WSAU Wausau· 3 days agoBy Leroy Leo and Christy Santhosh (Reuters) - AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica ...